Novel gels: implications for drug delivery

Paul, Swarnali Das; Sharma, Harish; Jeswani, Gunjan; Jha, Arvind Kumar

doi:10.1016/b978-0-323-46143-6.00012-9

Cited by 12 publications

(6 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was due to the increased swelling of the polymers, alongside the entrapment of CO 2 bubbles generated from the reaction of sodium bicarbonate with hydrochloric acid [202]. Furthermore, sodium bicarbonate acted as a source of sodium ions which promoted the in situ gelation of GG through the formation of a cross-linked, three-dimensional network [203][204][205][206]. Regarding the mucoadhesive capability of the tablets, increasing amounts of GG demonstrated an increasing mucoadhesive strength of the tablets onto goat stomach mucosa, due to increased water uptake and swelling and higher availability of adhesive polymer sites that could interact with the mucin molecules.…”

Section: Floating and Mucoadhesive Systemsmentioning

confidence: 99%

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

2021

View full text Add to dashboard Cite

There have been many efforts to improve oral drug bioavailability and therapeutic efficacy and patient compliance. A variety of controlled-release oral delivery systems have been developed to meet these needs. Gastroretentive drug delivery technologies have the potential to achieve retention of the dosage form in the upper gastrointestinal tract (GIT) that can be sufficient to ensure complete solubilisation of the drugs in the stomach fluids, followed by subsequent absorption in the stomach or proximal small intestine. This can be beneficial for drugs that have an “absorption window” or are absorbed to a different extent in various segments of the GIT. Therefore, gastroretentive technologies in tandem with controlled-release strategies could enhance both the therapeutic efficacy of many drugs and improve patient compliance through a reduction in dosing frequency. The paper reviews different gastroretentive drug delivery technologies and controlled-release strategies that can be combined and summarises examples of formulations currently in clinical development and commercially available gastroretentive controlled-release products. The different parameters that need to be considered and monitored during formulation development for these pharmaceutical applications are highlighted.

show abstract

Section: Floating and Mucoadhesive Systemsmentioning

confidence: 99%

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

2021

View full text Add to dashboard Cite

show abstract

“…Nanogels are produced with the use of natural or synthetic polymers by cross-linking hydrophilic polymer networks. The properties of the polymers from which they are synthesized confer nanogels with a number of advantages in terms of their use as a delivery system, the most important of which are that their size can be freely modified, that they generate a large surface area with numerous exposed functional groups, and that they ensure high stability and biocompatibility, as well as high load capacity [53,54]. It has also been shown that due to their physicochemical nature, nanoparticles are immunologically active, target specific cells and effectively protect antigens against degradation [55].…”

Section: Nanogelsmentioning

confidence: 99%

Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines

Karczmarzyk

Kęsik-Brodacka

2022

Pathogens

View full text Add to dashboard Cite

The sudden outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic in December 2019 caused crises and health emergencies worldwide. The rapid spread of the virus created an urgent need for the development of an effective vaccine and mass immunization to achieve herd immunity. Efforts of scientific teams at universities and pharmaceutical companies around the world allowed for the development of various types of preparations and made it possible to start the vaccination process. However, it appears that the developed vaccines are not effective enough and do not guarantee long-lasting immunity, especially for new variants of SARS-CoV-2. Considering this problem, it is promising to focus on developing a Coronavirus Disease 2019 (COVID-19) mucosal vaccine. Such a preparation applied directly to the mucous membranes of the upper respiratory tract might provide an immune barrier at the primary point of virus entry into the human body while inducing systemic immunity. A number of such preparations against SARS-CoV-2 are already in various phases of preclinical and clinical trials, and several of them are very close to being accepted for general use, constituting a milestone toward pandemic containment.

show abstract

“…Emulgels regard pharmaceutical dosage forms gathering emulsion and gel properties, which enables their use as a controlled topical delivery system [9]. Their production firstly involves the preparation of an emulsion by the hot emulsification method.…”

Section: Diclofenac Emulgel Productionmentioning

confidence: 99%

From Lab to Upscale—Boosting Formulation Performance through In Vitro Technologies

Miranda

Veloso

Cardoso³

et al. 2020

The 1st International Electronic Conference on Pharmaceutics

View full text Add to dashboard Cite

Pre-stability studies carried out throughout the development of a diclofenac emulgel formulation have shown a clear decrease in the drug release rate. In order to address the root-cause associated with this phenomena, product historical data were retrieved and analyzed following a retrospective Quality by Design (rQbD) approach. The quality target product profile (QTPP) was established, and risk assessment tools were used to identify the most relevant parameters affecting formulation performance. These consisted in (i) mixing time, (ii) sodium hydroxide content and (iii) carbopol grade. Following a 23 full factorial design, the pH, viscosity, in vitro release rate and cumulative amount of drug released at the end of the release experiment were selected as responses to statistically model the available data. It was observed that higher sodium hydroxide concentrations induce a decrease in viscosity, consequently resulting in a superior pharmaceutical performance. Moreover, as a secondary effect, a lower carbopol viscosity yields lower release outputs. The estimated models were used to define a feasible working region, which was further confirmed at an industrial scale. This work highlights the use of rQbD principles to achieve a greater product understanding. By doing so, specific strategies can be applied to product manufacture in order to consistently meet QTPP requirements.

show abstract

Novel gels: implications for drug delivery

Cited by 12 publications

References 89 publications

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications

Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines

From Lab to Upscale—Boosting Formulation Performance through In Vitro Technologies

Contact Info

Product

Resources

About